Pierre Fabre Medicament

Pierre Fabre S.a.

P. F. Medicament

Other

Jean-Pierre Rieu

Henri Cousse

Gilbert Mouzin

Andre Delhon

Gareth W John

Bruno Legrand

Dennis C Bigg

Jean-Fran&ccedil;ois Patoiseau

Yvan Verscheure

Thierry Imbert

Elisabeth Dupont-Passelaigue

Antoine Stenger

Alain Duflos

Jean-Francois Patoiseau

Didier Junquero

Jean-Pierre Tarayre

Pierre Sokoloff

Jean-Francedillaois Patoiseau

Karine Valeille

Samuel Mialhe

Jean-Pierre Valentin

Jean-François Patoiseau

Ludovic Leriche

Henry Cousse

Mike Briley

Elisabeth Dupont-passelaigue

The present invention concerns compounds of general formula (I) characterized in that (formula 1) wherein, in particular: &#x2014;Rrepresents one or more groups such as: trifluoromethyl, halogen such as F, Cl, &#x2014;when n=m=1, W represents CH then Y represents oxygen, &#x2014;U represents: &#x2022;either &#x2014;(C&#x2550;O)CHNH&#x2014; and is branched at position 4 of pyridazinone, then R2 represents H, &#x2022;or &#x2014;(C&#x2550;O)NH&#x2014; and U is branched at positions (4), (5) or (6) of pyridazinone, then R2 represents H, &#x2014;R3 represents a hydrogen or methyl and the addition salts with pharmaceutically acceptable bases and acids and the different isomers, and their mixtures in any proportion for use as SCD-1 enzyme inhibitors for the treatment of obesity, type-2 diabetes and lipid disorders. 

Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors

The present invention relates to chromone derivatives, their preparation, their pharmaceutical compositions and their application as D3 dopaminergic ligands as a medicament for disorders of the central nervous system.

Chromone derivatives, a process for their preparation and their therapeutic applications

The invention concerns compounds of formula (I) wherein: R1 and R2, identical or different, represent a saturated or unsaturated alkyl radical, branched or not and containing 1 to 7 carbon atoms; R3 to R8, identical or different, represent a hydrogen, an alkyl branched or not and containing 1 to 5 carbon atoms, an acyloxy, branched or not and containing 1 to 5 carbon atoms, a halogeno, nitro, hydroxy, acyl or alkoxy group containing 1 to 5 carbon atoms, a dialkylamino group containing 1 to 5 carbon atoms, a trifluoromethyl or trifluoro methoxyl group; Z represents an oxygen or sulphur atom or methylene; m represents an integer between 0 and 4 inclusively; n represents an integer between 2 and 7 inclusively; and their pure enantiomers and mixtures, the therapeutically acceptable mineral or organic salts of the compounds of formula (I) and their possible hydrates.

Substitute 1-(piperidin-4-yl)-3-(aryl)-isothioureas, their preparation and therapeutic use

Substituted 1-(4-piperidyl)-3-(aryl) isothioureas their preparation and their therapeutic application

Heterocyclic compounds for treating myocardial ischemia

Sulfonamides derived from benzocyclic or benzoheterocyclic acids, their

The invention relates to novel substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazin-4-ones of formula I ##STR1## their pharmaceutically acceptable inorganic or organic salts, optionally in their hydrated form, the racemates, the enantismers or their mixtures, their preparation and their use as medicaments as well as all the pharmaceutical compositions of I which are or are not combined with another active principle.

Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazin-4-ones and

The invention relates to the new 3-arylalkylaminoalkyl-4H-1,3-benzoxazin-4-one derivatives of general formula ##STR1## in which: R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be identical or different, denote a hydrogen, a branched or unbranched lower alkyl group or an alkyloxy, halo, nitro, amino, acylamino or dialkylamino group, and R.sub.1 and R.sub.2 on one hand and R.sub.3, R.sub.4 on the other hand can fuse to give a divalent group and more especially --OCH.sub.2 O--, --OCH.sub.2 CH.sub.2 O-- and --CH.dbd.CH--CH.dbd.CH--; R.sub.5 and R.sub.6, which may be identical or different, denote a hydrogen, a saturated or unsaturated, branched or unbranched alkyl group containing from 1 to 15 carbon atoms or a cycloalkyl group, and R.sub.5 and R.sub.6 can fuse to give a --(CH.sub.2).sub.p -- group with p=2 to 7; R.sub.7 denotes a hydrogen, a saturated or unsaturated, branched or unbranched alkyl group containing from 1 to 15 carbon atoms, a cycloalkyl group, a substituted or unsubstituted aryl and a substituted or unsubstituted arylalkyl; the values of m and n, which may be identical or different, can vary from 1 to 4 inclusive; as well as the therapeutically acceptable organic or inorganic salts of I. The compounds are useful as medicinal products in the treatment of disorders of the cardiovascular system.

2,3-dihydro-3-arylalkylaminoalkyl-4H-1,3-benzoxazin-4-one derivatives,

The invention relates to new derivatives of biphenyl primary alcohols, their preparation and use as medicaments useful in the treatment and prevention of atherosclerotic disorders. The new derivatives have the general formula ##STR1## in which X represents a halogen atom, and more particularly chlorine, bromine or fluorine in ortho or meta position,

Lipid- and cholesterol-reducing derivatives of halo-biphenyl primary

The invention concerns halo-biphenyl tertiary alcohols of the general formula: ##STR1## in which: X is chlorine or bromine in ortho or meta position.

Halo-biphenyl tertiary alcohols useful in therapy in the treatment of

The present invention relates to new 2-(arylalkyloxymethyl)morpholine derivatives, the preparation thereof and their application as drugs which are useful in the treatment of disorders of the central nervous system. The 2-(arylalkyloxymethyl)morpholine derivatives according to the invention correspond to the general formula (I): ##STR1## in which: Ar denotes an aromatic group and more especially the following radicals: ##STR2## in the case where Ar denotes a phenyl radical and R denotes a hydrogen atom, an alkyl, alkoxy or halogen group, a trifluoromethyl radical, a nitro or amino group, a hydroxy group or an arylalkyloxy group.

2-(arylalkyloxymethyl)morpholines and the central nervous system

This invention relates to new derivatives of biphenyl alkyl carboxylates, to a process for the preparation thereof and the use thereof as medicaments. The new derivatives according to the present invention correspond to general formula (I): ##STR1## wherein X represents a hydrogen atom or a halogen atom,

Derivatives of biphenyl alkyl carboxylates and their use as medicaments

This invention relates to new chemical compounds useful as drugs, as well as to pharmaceutical compositions containing the same. The new products are aromatic keto acid compounds with antiinflammatory as well as analgetic and hypocholesteremic activity and having the general formula ##STR1## wherein R.sub.1 is hydrogen, halogen, phenyl, halophenyl, phenoxy, or substituted phenoxy.

Aromatic keto acids and derivatives having analgetic, antiinflammatory,

This invention relates to new chemical compounds useful as drugs, as well as to pharmaceutical compositions containing the same. This application claims their hypocholesterolemic use. The new products are aromatic keto acid compounds with antiinflammatory as well as analgetic and hypocholesteremic acitvity and having the general formula: ##STR1## wherein R.sub.1 is hydrogen, halogen, phenyl, halophenyl, alkyl, phenoxy, or substituted phenoxy.

Method of reducing cholesterol using certain aromatic keto acids

Growing community of inventors

Castres, France

Jean-Pierre Rieu